World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
98
Citations
40803
World Ranking
8847
National Ranking
4557

Andrew Blauvelt publication distribution in Medicine in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Medicine in 2026. The highlighted bar marks where Andrew Blauvelt sits on this spectrum.

101–120 publications: 5 scientists 121–140 publications: 26 scientists 141–160 publications: 73 scientists 161–180 publications: 155 scientists 181–200 publications: 230 scientists 201–220 publications: 363 scientists 221–240 publications: 487 scientists 241–260 publications: 545 scientists 261–280 publications: 722 scientists 281–300 publications: 768 scientists 301–320 publications: 834 scientists 321–340 publications: 895 scientists 341–360 publications: 922 scientists 361–380 publications: 838 scientists 381–400 publications: 861 scientists 401–420 publications: 918 scientists 421–440 publications: 806 scientists 441–460 publications: 771 scientists 461–480 publications: 751 scientists 481–500 publications: 713 scientists 501–520 publications: 617 scientists 521–540 publications: 611 scientists 541–560 publications: 537 scientists 561–580 publications: 504 scientists 581–600 publications: 509 scientists 601–620 publications: 396 scientists 621–640 publications: 386 scientists 641–660 publications: 371 scientists 661–680 publications: 340 scientists 681–700 publications: 336 scientists 701–720 publications: 307 scientists 721–740 publications: 259 scientists 741–760 publications: 230 scientists 761–780 publications: 228 scientists 781–800 publications: 217 scientists 801–820 publications: 204 scientists 821–840 publications: 186 scientists 841–860 publications: 177 scientists 861–880 publications: 155 scientists 881–900 publications: 139 scientists 901–920 publications: 145 scientists 921–940 publications: 116 scientists 941–960 publications: 133 scientists 961–980 publications: 91 scientists 981–1,000 publications: 96 scientists 1,001–1,020 publications: 77 scientists 1,021–1,040 publications: 70 scientists 1,041–1,060 publications: 63 scientists 1,061–1,080 publications: 77 scientists 1,081–1,100 publications: 49 scientists 1,101–1,120 publications: 54 scientists 1,121–1,140 publications: 49 scientists 1,141–1,160 publications: 51 scientists 1,161–1,180 publications: 35 scientists 1,181–1,200 publications: 39 scientists 1,201–1,220 publications: 26 scientists 1,221–1,240 publications: 37 scientists 1,241–1,260 publications: 36 scientists 1,261–1,280 publications: 27 scientists 1,281–1,300 publications: 32 scientists 1,301–1,320 publications: 28 scientists 1,321–1,340 publications: 17 scientists 1,341–1,360 publications: 30 scientists 1,361–1,380 publications: 28 scientists 1,381–1,400 publications: 17 scientists 1,401–1,420 publications: 21 scientists 1,421–1,440 publications: 15 scientists 1,441–1,460 publications: 12 scientists 1,461–1,480 publications: 12 scientists 1,481–1,500 publications: 18 scientists 1,501–1,520 publications: 14 scientists 1,521–1,540 publications: 17 scientists 1,541–1,560 publications: 15 scientists 1,561–1,580 publications: 6 scientists 1,581–1,600 publications: 2 scientists 1,601–1,620 publications: 12 scientists 1,621–1,640 publications: 11 scientists 1,641–1,660 publications: 8 scientists 1,661–1,680 publications: 5 scientists 1,681–1,700 publications: 5 scientists 1,701–1,720 publications: 10 scientists 1,721–1,740 publications: 12 scientists 1,741–1,760 publications: 14 scientists 1,761–1,780 publications: 6 scientists 1,781–1,795 publications: 5 scientists 1,796+ publications: 100 scientists
101 publications 1,796+

This scientist: 604 publications — 72nd percentile

72% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 1,796 publications or more.

Andrew Blauvelt D-index placement in Medicine in 2026

The chart shows the D-index (discipline H-index) distribution of Medicine scientists ranked by Research.com in 2026. The highlighted bar marks where Andrew Blauvelt sits on this spectrum.

70–71 D-Index: 226 scientists 72–73 D-Index: 391 scientists 74–75 D-Index: 574 scientists 76–77 D-Index: 730 scientists 78–79 D-Index: 891 scientists 80–81 D-Index: 972 scientists 82–83 D-Index: 1,027 scientists 84–85 D-Index: 1,003 scientists 86–87 D-Index: 960 scientists 88–89 D-Index: 970 scientists 90–91 D-Index: 922 scientists 92–93 D-Index: 839 scientists 94–95 D-Index: 808 scientists 96–97 D-Index: 779 scientists 98–99 D-Index: 668 scientists 100–101 D-Index: 611 scientists 102–103 D-Index: 630 scientists 104–105 D-Index: 513 scientists 106–107 D-Index: 541 scientists 108–109 D-Index: 445 scientists 110–111 D-Index: 429 scientists 112–113 D-Index: 400 scientists 114–115 D-Index: 393 scientists 116–117 D-Index: 318 scientists 118–119 D-Index: 302 scientists 120–121 D-Index: 287 scientists 122–123 D-Index: 255 scientists 124–125 D-Index: 256 scientists 126–127 D-Index: 252 scientists 128–129 D-Index: 230 scientists 130–131 D-Index: 179 scientists 132–133 D-Index: 168 scientists 134–135 D-Index: 163 scientists 136–137 D-Index: 159 scientists 138–139 D-Index: 134 scientists 140–141 D-Index: 134 scientists 142–143 D-Index: 118 scientists 144–145 D-Index: 109 scientists 146–147 D-Index: 106 scientists 148–149 D-Index: 74 scientists 150–151 D-Index: 79 scientists 152–153 D-Index: 80 scientists 154–155 D-Index: 87 scientists 156–157 D-Index: 57 scientists 158–159 D-Index: 74 scientists 160–161 D-Index: 69 scientists 162–163 D-Index: 60 scientists 164–165 D-Index: 53 scientists 166–167 D-Index: 39 scientists 168–169 D-Index: 42 scientists 170–171 D-Index: 32 scientists 172–173 D-Index: 39 scientists 174–175 D-Index: 40 scientists 176–177 D-Index: 28 scientists 178–179 D-Index: 19 scientists 180–181 D-Index: 23 scientists 182–183 D-Index: 31 scientists 184–185 D-Index: 18 scientists 186–187 D-Index: 20 scientists 188–189 D-Index: 22 scientists 190–191 D-Index: 13 scientists 192–193 D-Index: 21 scientists 194–195 D-Index: 12 scientists 196–197 D-Index: 12 scientists 198–199 D-Index: 14 scientists 200–201 D-Index: 15 scientists 202–203 D-Index: 13 scientists 204–205 D-Index: 10 scientists 206–207 D-Index: 8 scientists 208–209 D-Index: 4 scientists 210–211 D-Index: 12 scientists 212–213 D-Index: 11 scientists 214–215 D-Index: 10 scientists 216 D-Index: 4 scientists 217+ D-Index: 98 scientists
70 D-Index 217+

This scientist: 98 D-Index — 57th percentile

57% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 217 D-Index or more.

Overview

Andrew Blauvelt is affiliated with the Veterans Health Administration in the United States. Their research primarily focuses on Medicine and Immunology and Microbiology, with a significant emphasis on Immunology, Dermatology, Immunology and Allergy, Physiology, and Pediatrics, Perinatology and Child Health as key subfields.

The scientist's work concentrates on major topics such as psoriasis treatment and pathogenesis, dermatology and skin diseases, asthma and respiratory diseases, pharmaceutical studies and practices, health systems including economic evaluations and quality of life, food allergy and anaphylaxis research, and autoimmune bullous skin diseases.

Andrew Blauvelt's notable recent papers include:

  • Efficacy and Safety of Upadacitinib vs Dupilumab in Adults With Moderate-to-Severe Atopic Dermatitis, 2021, JAMA Dermatology
  • Once-daily upadacitinib versus placebo in adolescents and adults with moderate-to-severe atopic dermatitis (Measure Up 1 and Measure Up 2): results from two replicate double-blind, randomised controlled phase 3 trials, 2021, The Lancet
  • Tralokinumab for moderate-to-severe atopic dermatitis: results from two 52-week, randomized, double-blind, multicentre, placebo-controlled phase III trials (ECZTRA 1 and ECZTRA 2), 2020, British Journal of Dermatology
  • Bimekizumab versus Secukinumab in Plaque Psoriasis, 2021, New England Journal of Medicine
  • Efficacy and Safety of Lebrikizumab, a High-Affinity Interleukin 13 Inhibitor, in Adults With Moderate to Severe Atopic Dermatitis, 2020, JAMA Dermatology

Frequent co-authors in their research include Mark Lebwohl, Kim Papp, April W. Armstrong, Melinda Gooderham, and Eric L. Simpson.

The scientist frequently publishes in journals such as the Journal of the American Academy of Dermatology, SKIN The Journal of Cutaneous Medicine, British Journal of Dermatology, Journal of Investigative Dermatology, and Dermatology and Therapy. These venues reflect a strong concentration on dermatology and skin-related medical research.

Best Publications

  • Two Phase 3 Trials of Dupilumab versus Placebo in Atopic Dermatitis

    Eric L. Simpson;Thomas Bieber;Emma Guttman-Yassky;Lisa A. Beck

  • Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): a 1-year, randomised, double-blinded, placebo-controlled, phase 3 trial

    Andrew Blauvelt;Marjolein de Bruin-Weller;Melinda Gooderham;Jennifer C. Cather

  • Human skin Langerhans cells are targets of dengue virus infection.

    Shuenn-Jue L. Wu;Geraldine Grouard-Vogel;Wellington Sun;John R. Mascola

  • Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the continuous treatment of patients with moderate to severe psoriasis: Results from the phase III, double-blinded, placebo- and active comparator–controlled VOYAGE 1 trial

    Andrew Blauvelt;Kim A. Papp;Christopher E.M. Griffiths;Bruce Randazzo;Bruce Randazzo

  • Phase 3 Trials of Ixekizumab in Moderate-to-Severe Plaque Psoriasis

    Kenneth B Gordon;Jean-Frederic Colombel;Dana S Hardin

  • Circulating Th17, Th22, and Th1 cells are increased in psoriasis.

    Shinji Kagami;Heather L. Rizzo;Jennifer J. Lee;Yoshinobu Koguchi

  • IL-17 is essential for host defense against cutaneous Staphylococcus aureus infection in mice

    John S. Cho;Eric M. Pietras;Nairy C. Garcia;Romela Irene Ramos

  • Efficacy and safety of dupilumab in adults with moderate-to-severe atopic dermatitis inadequately controlled by topical treatments: a randomised, placebo-controlled, dose-ranging phase 2b trial.

    Diamant Thaçi;Eric L Simpson;Lisa A Beck;Thomas Bieber

  • Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate to severe plaque psoriasis: CLEAR, a randomized controlled trial

    Diamant Thaçi;Andrew Blauvelt;Kristian Reich;Tsen-Fang Tsai

  • Efficacy and safety of risankizumab in moderate-to-severe plaque psoriasis (UltIMMa-1 and UltIMMa-2): results from two double-blind, randomised, placebo-controlled and ustekinumab-controlled phase 3 trials

    Kenneth B Gordon;Bruce Strober;Mark Lebwohl;Matthias Augustin

  • Tildrakizumab versus placebo or etanercept for chronic plaque psoriasis (reSURFACE 1 and reSURFACE 2): results from two randomised controlled, phase 3 trials

    Kristian Reich;Kim A Papp;Andrew Blauvelt;Stephen K Tyring

  • Tralokinumab for moderate‐to‐severe atopic dermatitis: results from two 52‐week, randomized, double‐blind, multicentre, placebo‐controlled phase III trials (ECZTRA 1 and ECZTRA 2)*

    A. Wollenberg;A. Blauvelt;E. Guttman‐Yassky;M. Worm

  • Th17 cytokines stimulate CCL20 expression in keratinocytes in vitro and in vivo: implications for psoriasis pathogenesis.

    Erin G. Harper;Changsheng Guo;Heather Rizzo;Joseph V. Lillis

  • Risankizumab versus Ustekinumab for Moderate-to-Severe Plaque Psoriasis.

    Kim A. Papp;Andrew Blauvelt;Michael Bukhalo;Melinda Gooderham

  • Expression and function of CCR5 and CXCR4 on human Langerhans cells and macrophages: Implications for HIV primary infection

    M Zaitseva;A Blauvelt;S Lee;C K Lapham

  • Efficacy and Safety of Dupilumab in Adolescents With Uncontrolled Moderate to Severe Atopic Dermatitis: A Phase 3 Randomized Clinical Trial.

    Eric L. Simpson;Amy S. Paller;Elaine C. Siegfried;Mark Boguniewicz

  • Prevention of Vaginal SHIV Transmission in Rhesus Macaques Through Inhibition of CCR5

    Michael M Lederman;Ronald S Veazey;Robin Ewart Offord;Donald E Mosier

  • Pathophysiology of psoriasis: recent advances on IL-23 and Th17 cytokines.

    Erin Fitch;Erin Harper;Iliyana Skorcheva;Stephen E. Kurtz

  • A prospective phase III, randomized, double-blind, placebo-controlled study of brodalumab in patients with moderate-to-severe plaque psoriasis†

    K.A. Papp;K. Reich;C. Paul;A. Blauvelt

  • IL-17 is essential for host defense against cutaneous Staphylococcus aureus infection

    John Cho;Eric Pietras;Nairy Garcia;Romela Irene Ramos

Frequent Co-Authors

Kim Papp
Kim Papp Probity Medical Research
Kristian Reich
Kristian Reich University of Göttingen
Mark Lebwohl
Mark Lebwohl Icahn School of Medicine at Mount Sinai
Craig L. Leonardi
Craig L. Leonardi Saint Louis University
Alice B. Gottlieb
Alice B. Gottlieb Icahn School of Medicine at Mount Sinai
Kenneth B. Gordon
Kenneth B. Gordon Medical College of Wisconsin
Diamant Thaçi
Diamant Thaçi University of Lübeck
Christopher E.M. Griffiths
Christopher E.M. Griffiths University of Manchester
Eric L. Simpson
Eric L. Simpson Oregon Health & Science University
Neil M.H. Graham
Neil M.H. Graham Regeneron (United States)

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Exploring alternative career pathways in healthcare is becoming increasingly accessible with the rise of online degree programs. Students who want to pursue a medical career but may not follow the traditional MD route have a variety of affordable and flexible options to consider.

For those interested in healthcare administration and technology, a health information technology online degree offers a path into a growing field focused on the management of patient data. Similarly, students looking for entry-level roles in healthcare can explore the medical billing and coding online courses cost to find budget-friendly ways to get certified remotely.

Nursing remains a popular and rewarding option. There are a range of online nurse practitioner programs that allow registered nurses to advance their qualifications fully online. Aspiring RNs can also benefit from the cheapest rn to bsn online programs to boost credentials affordably and conveniently.

Each of these pathways provides students with a flexible and cost-effective way to enter or advance in the healthcare sector, making them excellent alternatives or complements to traditional medical studies.

Best Scientists Citing Andrew Blauvelt

Trending Scientists

Recently Published Articles